Reprocell Acquires BioServe, Reinnervate | GenomeWeb

NEW YORK (GenomeWeb) – Japanese stem cell products company Reprocell said today that it has purchased 3D cell culture firm Reinnervate and US genomics services firm BioServe.

Sedgefield, UK-based Reinnervate makes the Alvetex line of 3D cell culture products, which will be combined with Reprocell's induced pluripotent stem cells to produce next-generation tools for drug toxicity, neuroscience, and cancer research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.